---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-068813"
form_type: "8-K"
ticker: "DCOY"
cik: "0001615219"
company_name: "Decoy Therapeutics Inc."
filed_at: "2026-02-25T23:59:59+00:00"
generated_at: "2026-05-16T00:19:12.916562+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Decoy Therapeutics shareholders approve 2026 equity plan and reverse stock split

## Summary
- Approved 2026 Equity Incentive Plan: 351,837 for, 68,978 against, 55,703 abstentions.
- Approved reverse stock split of common stock at ratio between 1:4 and 1:15, at board's discretion.
- Reverse split proposal: 2,187,125 votes for, 507,474 against, 2,173 abstentions.
- Adjournment proposal was unnecessary due to sufficient votes; broker non-votes totaled 2,220,254.

## SEC filing metadata
- accession: 0001193125-26-068813
- form_type: 8-K
- ticker: DCOY
- cik: 0001615219
- company_name: Decoy Therapeutics Inc.
- filed_at: 2026-02-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1615219/000119312526068813/0001193125-26-068813-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1615219/000119312526068813/dcoy-20260224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-068813
- JSON: https://secwatch.observer/filing/0001193125-26-068813.json
- Plain text: https://secwatch.observer/filing/0001193125-26-068813.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.